Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting
Details of the Company's progress in engineering this portfolio are included in two abstracts published today for presentation as posters at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition (
The abstracts describe how, through antibody engineering,
CD37 is a protein abundant on the surface of B cells but absent in haematopoietic stem cells and plasma cells. Its expression pattern makes it attractive as a therapeutic target for B-cell malignancies, including non-Hodgkin lymphomas and chronic lymphocytic Leukemia and for B-cell-driven autoimmune disorders, especially where an alternative to standard anti-CD20 immunotherapy is sought.
Details of the abstracts to be presented at ASH are as follows:
Abstract 1351
Abstract title: NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies
Authors:
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Date:
Presentation Time:
Location:
Abstract 2679
Abstract title: B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life
Authors:
Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
Session Date: Sunday, 11 December
Presentation Time:
Location:
IR enquiries
Malene Brondberg, interim CEO & CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Tel: +44 203 928 6900
Email:
nordicnanovector@medistrava.com
About
- Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma (NHL);
- Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the alpha-emitting radionuclide lead-212, currently being explored with partner Oranomed for chronic lymphocytic leukaemia;
- Multiple fully humanized anti-CD37 antibodies with potential in haematological cancers and autoimmune diseases; and
- A CD37
DOTA CAR-T cell opportunity in haematological cancers, which is being advanced via a research collaboration with theUniversity of Pennsylvania .
Further information can be found at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking statements relating to inter alia to the business and strategies, financial performance and results of the Company. Forward-looking statements concern future circumstances and results and other statements that are not historical facts. These statements are based on
The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of
